All the taco-esk meat dishes!

that checkpoint inhibitor drugs such as anti-PD-1 therapy -already used in hospitals- work best when they expand these stem-like and metabolically fit T-cells. In contrast, people whose immune reactions were regulated by exhausted cells fared badly. When checkpoint therapy was administered with

“stem-like" T-cells. These cells, characterized by genes TCF1 and LEF1, could self-renew and differentiate into new waves of fighters. If these cells were removed from mouse models, immune attacks collapsed; if they were grown, tumors disappeared and survival increased. Researchers also discovered

chemical messenger that recruits other immune defenses. The studies showed that metabolic flexibility, not target recognition, foretells how long the immune cells will keep fighting. Among the populations of tumor-infiltrating T-cells that were so diverse, one stood out as extraordinary: a subset of

glycolysis, they switched to oxidative phosphorylation and fatty acid metabolism- an energy strategy that enables them to endure the long term. When researchers boosted these channels of energy in mice, the T-cells killed tumor cells better and produced higher levels of interferon-γ, an immune

single-cell resolution, the researchers identified a minor subset of tumor-cytotoxic cells. These cells continue to function even in oxygen-starved, nutrient-poor environments in which other immune cells do not. These hardy T-cells employed a second fuel source. Instead of combusting glucose through

patients, the treatments fail because immune cells become exhausted. Tumors naturally adapt to disable or tire out the same cells meant to kill them. Researchers mapped how CD8⁺ T cells-the body's own killers-are capable of surviving and fighting within solid tumors. By examining the cells at

place. Taken together, the breakthroughs promise a day when the body's own immune system can prevent and fight cancer with greater accuracy and endurance. Cancer immunotherapy transformed the treatment of most cancers by unleashing the potential of the immune system to kill tumors. Yet, in most

In a breakthrough that could potentially rewrite the prevention and treatment of cancer, researchers have discovered how certain immune cells can break through tumors’ defenses. They have also developed a new nanoscale vaccine that shows promise in preventing cancers from occurring in the first

Melanoma, pancreatic cancer, and triple-negative breast cancer (TNBC) are each serious clinical challenges due to how common or aggressive they are and how poorly they often respond to treatment. Which is why researchers are determined to develop an effective treatment for all of them.

Researchers envision their vaccine being used as both a treatment and a preventive, and as an approach to treating multiple cancer types. NOTE: This is PRECLINICAL.
• www.umass.edu/news/article...

The study has been published in Cell. YES, it is PEER-REVIEWED.
• www.cell.com/cell-reports...

🧪🧵⬇️

It's a tradition in Scotland for the road gritters too

Most of Deals art is still packed in our house— Ken has it.